# Incannex Healthcare (IXHL) — News

IXHL · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/ixhl/news

## Recent headlines

- [Incannex announces first patient dosed in Dreamzz phase 2 study of IHL-42X](https://www.ainvest.com/news/incannex-announces-patient-dosed-dreamzz-phase-2-study-ihl-42x-2608) — AInvest Wire, Aug 25, 2026
  Incannex Healthcare Inc. (Nasdaq: IXHL) announced first patient dosed in DReAMzz Phase 2 crossover study of IHL-42X, its lead oral drug candidate for the treatment of obstructive sleep apnea (OSA). The study is designed to evaluate multiple ratios of the two active pharmaceutical…
- [Incannex receives additional A$5.1 million R&D tax incentive refund, completing more than A$11.2 million in non-dilutive capital received in 2026](https://www.ainvest.com/news/incannex-receives-additional-5-1-million-tax-incentive-refund-completing-11-2-million-dilutive-capital-received-2026-2608) — AInvest Wire, Aug 11, 2026
- [Incannex Healthcare - receives final A$5.1 mln R&D tax incentive refund for FY25 - SEC filing](https://www.ainvest.com/news/incannex-healthcare-receives-final-5-1-mln-tax-incentive-refund-fy25-sec-filing-2608) — AInvest Wire, Aug 11, 2026
  Incannex Healthcare Inc. (NASDAQ: IXHL) has received the final A$5.1 million in refunds under the Australian Government’s Research and Development Tax Incentive Program for fiscal year 2025, bringing the total non-dilutive funding received in 2026 to more than A$11.1 million. This follows an…
- [Algorae Pharmaceuticals Ltd-Nasdaq pharma chairman Troy Valentine joins Algorae board](https://www.ainvest.com/news/algorae-pharmaceuticals-nasdaq-pharma-chairman-troy-valentine-joins-algorae-board-2607) — AInvest Wire, Jul 14, 2026
  Troy Valentine, Executive Director and co-founder of Alignment Capital Pty Ltd., has joined the board of Algorae Pharmaceuticals Ltd. as a director. Valentine brings extensive experience in finance and corporate governance, having previously served as Chairman of Incannex Healthcare , Inc., a role…
- [Incannex Healthcare - patent for IHL-42X expires July 9, 2040; extension possible after FDA approval - SEC filing](https://www.ainvest.com/news/incannex-healthcare-patent-ihl-42x-expires-july-9-2040-extension-fda-approval-sec-filing-2606) — AInvest Wire, Jun 25, 2026
  Incannex Healthcare Inc. (Nasdaq: IXHL) has disclosed in a recent SEC filing that the patent for its lead drug candidate, IHL-42X, is set to expire on July 9, 2040. The company noted that patent term extension may be possible following regulatory approval by the U.S. Food and Drug Administration…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).